Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + selumetinib in KRAS-mutant, PIK3CA-wildtype advanced non-small cell lung cancer and colorectal cancer
NL-OMON47757Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of afatinib and selumetinib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoints: Incidence of dose-limiting toxicities and Progression-free survival. Started Jun 2015; status: active, not recruiting.
02
Drugs
afatinibselumetinib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON47757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47757.